Patients living with HIV should receive isoniazid-preventative therapy (IPT) in order to prevent tuberculosis (TB). In South Africa, IPT implementation has decelerated. Stigma is frequently found to be a barrier to treatment. We sought to understand community members' perceptions of TB and HIV stigma in order to inform future IPT implementation efforts. S52 • OFID 2019:6 (Suppl 2) • Oral Abstracts Methods. The study was conducted in the rural KwaZulu Natal province of South Africa. Community members were interviewed anonymously and answers to interview questions were scored to represent stigma. Three different domains of TB knowledge were evaluated: causes, transmission, and treatment and prevention of TB. All three knowledge scores were added to create a total knowledge of TB score. A 7-item scale was used to assess stigma; presence of stigma was defined as 1 or more positive responses on the scale. Descriptive statistics, chi-square tests, linear regression, and Kruskal-Wallis tests were performed.
Background. Bedaquiline and delamanid are new and much-needed treatment options for drug-resistant tuberculosis (TB); however, there are limited data guiding their use and no direct comparison of the two drugs. We thus sought to compare the clinical outcomes of patients with drug-resistant tuberculosis receiving either a bedaquiline-or delamanid-based treatment regimen.
Methods. This is a prospective observational study among patients with drug-resistant pulmonary TB in the country of Georgia from 2015 to 2017. Patients receiving bedaquiline or delamanid were eligible to be enrolled. Monthly sputum cultures and MIC testing on Mycobacterium tuberculosis isolates were performed. Clinical outcomes included time to culture conversion, rate of acquired drug resistance and treatment outcomes.
Results. Among 156 patients with MDR-TB who were approached, 100 were enrolled, and 95 were receiving a bedaquiline (n = 64) or delamanid (n = 31) based regimen and included in the study. Patients receiving bedaquiline or delamanid were similar with regards to age, BMI, substance use, comorbidities, rate of cavitary disease, and extensively drug-resistant (XDR) TB. Rates of additional Class A drug use including linezolid (78 vs. 81%) and a fluoroquinolone (39 vs. 36%) were similar and the mean effective drugs received per group was 4 (IQR 3-4, P = 0.33). Median drug duration was 171 days for bedaquiline and 182 days for delamanid; no patient discontinued due to QT C prolongation. Adjusted cumulative culture conversion rates at 60 days (64% vs. 48%, P = 0.14) and 180 days (95% vs. 77%, P = 0.02) were higher in patients receiving bedaquiline compared with delamanid (see figure) . Rates of acquired drug resistance were higher in patients receiving delamanid compared with bedaquiline (35 vs. 12%, P < 0.01). Lastly, patients receiving a bedaquiline-based regimen had higher rates of favorable outcomes as compared with patients receiving delamanid (94% vs. 67%, P < 0.01).
Conclusion. Patients receiving bedaquiline-and delamanid-based treatment regimens for drug-resistant TB had similar characteristics and those receiving bedaquiline had better clinical outcomes. Our results provide an important first comparison of bedaquiline vs. delamanid containing regimens.
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T-helper 1 (Th1) Production of Interferon Gamma (IFNγ) Is Directly Inhibited by TGFβ Within Pulmonary Mycobacterium tuberculous (Mtb) Granulomas
Benjamin H. Gern, MD 1 ; Kristin Adams, PhD 1 ; Caleb Stoltzfus, PhD 2 ; Courtney Plumlee, PhD 1 ; Michael Gerner, PhD 2 and Kevin Urdahl, MD, PhD 1 ; 1 Seattle Children's, Seattle, Washington; 2 University of Washington, Seattle, Washington Session: 198. Tuberculosis: Stigma, Diagnosis, and Treatment Friday, October 4, 2019: 4:00 PM Background. CD4 T-cell production of IFNɣ is essential to prevent dissemination of pulmonary Mtb, though is less effective at controlling infection within the lung. Because T cells are most effective in the context of direct interactions with Mtbinfected cells, we sought to determine the location of CD4 T-cell antigen sensing and IFNɣ production within granulomas.
Methods. We used a murine ultra-low-dose aerosol infection, developed by our lab, where most mice are infected by a single bacillus, resulting in a solitary granuloma that is more similar to human granulomas. We examined the lungs of wild-type mice 35 days later for patterns of T-cell activation with quantitative confocal imaging. This analysis was next performed following adoptive co-transfer of Th1 polarized Mtb-specific cells and control cells of irrelevant specificity (OVA). To determine the effect of TGFβ on IFNɣ production, we examined mice that lack the TGFβR on T cells (TGFβR.KO). Finally, we examined whether this effect was Th1 cell-intrinsic with an adoptive transfer of Th1-polarized Mtb-specific cells with (Tg.WT) and without (Tg.KO) the TGFβR.
Results. Despite many CD4 T cells localizing to the granuloma and undergoing T-cell receptor (TCR) activation (pS6), IFNɣ production was not significantly increased in the granuloma compared with a distal lung site (Figure 1 ). This pattern of localization and activation was found to be similar in the Mtb-specific (but not control) Th1 cells ( Figure  2) . In contrast, CD4 T cells from TGFβR.KO mice produced more IFNɣ within the granuloma (Figure 3) . Lastly, Tg.KO cells transferred into wild-type mice produced increased IFNɣ compared with Tg.WT, mirroring the findings in TGFβR.KO mice (Figure 4) .
Conclusion. CD4 T cell production of IFNɣ is decreased within the granuloma, where it can be most effective, despite evidence of ongoing TCR stimulation in Mtbspecific cells. We have shown that by alleviating the effects of TGFβ signaling, even terminally-differentiated Mtb-specific Th1 cells can produce more IFNɣ within the granuloma. While this modest increase suggests that there are additional mechanisms at play which warrant further exploration, these findings have the potential to guide immunotherapeutic development, especially given that TGFβ inhibitors are already in phase III clinical trials for other purposes.
